GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 636 participants.
Also called NCT03821129
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 636 participants
- Sponsor
- Registry
-
NCT03821129
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT03821129. Allocation not applicable; no masking; primary purpose prevention. Start 2019-07-25 (actual); primary completion 2028-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- Acronym
- REDUCE PAS
- Condition
- Stroke
- Condition
- PFO - Patent Foramen Ovale
- Intervention (Device)
- PFO closure with GORE® CARDIOFORM Septal Occluder
- Lead sponsor
- W.L.Gore & Associates
Record details
- Record id
cardio:ct-nct03821129- Content hash
4a00beb190375def5eeec9d8b41c60d46ebd8644cc197962574d7c8a93dd9851